MECP2 reactivation is a cornerstone therapeutic strategy at RSRT. The fact that this strategy is relevant to any and all MECP2 mutations and the fact it should not result in overexpression issues makes it an attractive approach. Expanding knowledge around the mechanics of X chromosome inactivation coupled with advances in scientific technologies that allow for targeting the MECP2 gene makes this an opportune time to double down on our efforts. Thanks to the generosity of our donors RSRT has made a $1.1 million award to Drs. Antonio Bedalov and Kyle Fink.
Register for the upcoming webinar to learn how these scientists are joining forces in their attack on Rett Syndrome. Learn what has already been accomplished and what is in the works to make this strategy a clinical reality. We welcome your questions.